SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001193125-23-295302
Filing Date
2023-12-14
Accepted
2023-12-14 13:33:26
Documents
1
Group Members
ALBERT CHADANIEL ESTESFHMLS X, L.L.C.FHMLS X, L.P.FHMLS XI, L.L.C.FHMLS XI, L.P.FHMLSP OVERAGE, L.L.C.FHMLSP OVERAGE, L.P.FHMLSP, L.L.C.FHMLSP, L.P.FRAZIER LIFE SCIENCES PUBLIC OVERAGE FUND, L.P.FRAZIER LIFE SCIENCES X, L.P.FRAZIER LIFE SCIENCES XI, L.P.J

Document Format Files

Seq Description Document Type Size
1 SC 13D/A d796217dsc13da.htm SC 13D/A 388302
  Complete submission text file 0001193125-23-295302.txt   390749
Mailing Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142 (857) 999-0075
KalVista Pharmaceuticals, Inc. (Subject) CIK: 0001348911 (see all company filings)

IRS No.: 200915291 | State of Incorp.: DE | Fiscal Year End: 0430
Type: SC 13D/A | Act: 34 | File No.: 005-88797 | Film No.: 231486496
SIC: 2834 Pharmaceutical Preparations

Mailing Address TWO UNION SQUARE, 601 UNION ST. SUITE 3200 SEATTLE WA 98101
Business Address TWO UNION SQUARE, 601 UNION ST. SUITE 3200 SEATTLE WA 98101 650-325-5156
Frazier Life Sciences Public Fund, L.P. (Filed by) CIK: 0001863769 (see all company filings)

IRS No.: 862999645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A